000 03214nam a22004575c 4500
999 _c7667
_d7667
001 7667
003 ES-MaUEC
005 20200716122645.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 190424s2019 gw a s |||| 0|eng d
020 _a9783030113926
024 7 _a10.1007/978-3-030-11392-6
_2doi
040 _bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRB45
_b.C47 2019 EB
245 0 0 _aChronic Lymphocytic Leukemia
_cedited by Michael Hallek, Barbara Eichhorst, Daniel Catovsky.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2019.
300 _aVI, 179 páginas 23 ilustraciones, 19 ilustraciones a color
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 1 _aHematologic Malignancies,
_x2197-9766
490 0 _aMedicine (Springer-11650)
505 0 _aPathophysiolgoy -- Diagnostics -- Clinical Presentation -- Prognostic Markers -- Treatment -- Follow-up and Complications -- Related Entities.
520 3 _aThis book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapy of T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed. .
988 _aPrimersemestre_2019_Medicine
650 1 4 _aHematology.
_0http://scigraph.springernature.com/things/product-market-codes/H3307X
653 0 _aHematology.
653 0 _aOncology  .
700 1 _aHallek, Michael.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aEichhorst, Barbara.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aCatovsky, Daniel.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106937
776 0 8 _iPrinted edition:
_z9783030113919
776 0 8 _iPrinted edition:
_z9783030113933
830 0 _aHematologic Malignancies,
_x2197-9766
_9133681
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-11392-6
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0